BioMarin, 5% jump follows global Yuviwel patent settlement with Ascendis

3-Line Briefing

• BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S announced a binding global patent settlement concerning Ascendis’s achondroplasia drug Yuviwel, and Yahoo Finance reports that BioMarin shares rose 5% on August 31.
• Ascendis will pay BioMarin royalties equal to 20% of Yuviwel net sales in the United States and 18% in the European Union, Brazil and South Korea through May 20, 2030, according to Yahoo Finance.
• BioMarin will drop its Section 337 investigation at the US International Trade Commission and grant Ascendis a non-exclusive, worldwide, royalty-bearing license for navepegritide, Yuviwel’s active compound, Yahoo Finance reports.

What Changes in the Yuviwel Patent Dispute

The immediate investor significance is a shift from litigation exposure to defined contractual economics. Yahoo Finance reports that the settlement resolves litigation pending in numerous jurisdictions, including the US International Trade Commission proceeding. That removes the specific dispute framework in which BioMarin alleged patent infringement while Ascendis’s medicine was under FDA assessment.

Yuviwel is a treatment for achondroplasia, a genetic condition that inhibits bone growth. The companies’ conflict involved competing achondroplasia treatments. BioMarin filed a complaint with the US International Trade Commission, while Ascendis filed a declaratory judgment action in federal court in California and argued that its regulatory-approval-related conduct was protected by the safe-harbor regulation, according to Yahoo Finance.

The dispute also reached the US Court of Appeals for the Federal Circuit, where the companies argued over procedural questions involving which forum should hear the matter first. Under the settlement, BioMarin agreed to drop the Section 337 investigation. For investors, Yahoo Finance’s account indicates that the legal question is being replaced by a royalty relationship, although Ascendis described the arrangement as a binding term sheet awaiting a definitive agreement.

Royalty Mechanics Set the Economic Trade-Off

Ascendis will pay BioMarin 20% of Yuviwel’s net sales in the United States through May 20, 2030, and 18% of net sales in the European Union, Brazil and South Korea through the same date, Yahoo Finance reports. The US royalty is retroactive to Yuviwel’s first commercial sale. The fact sheet does not provide Yuviwel’s future sales, the settlement’s total financial value or any upfront settlement payment.

That structure gives BioMarin an economic claim tied directly to Yuviwel sales without requiring the company to commercialize Yuviwel under the license arrangement. Yahoo Finance quotes BioMarin CEO Alexander Hardy saying the settlement encourages continued investment in long-term innovation needed to bring breakthrough treatments to patients. The practical value of that claim, however, depends on the sales base that generates royalties and on the payment period ending May 20, 2030.

Ascendis receives a non-exclusive, worldwide, royalty-bearing license for navepegritide. Yahoo Finance reports that the license allows Ascendis to continue studying, developing, manufacturing and commercializing the medication without restrictions. The trade-off is that the 20% US and 18% specified-market royalties reduce Yuviwel’s net economics during the period covered by the settlement.

By the Numbers: Market Reaction and Ownership

BioMarin’s stock rose 5% on August 31 after the settlement announcement, according to Yahoo Finance. That move is consistent with investors assigning value to a defined royalty stream and reduced litigation uncertainty, but the fact sheet does not disclose a dollar valuation for the royalties or a forecast for Yuviwel sales.

Institutional positioning changed before the announcement. Yahoo Finance reports that the number of hedge funds holding BioMarin fell from 62 in the first quarter to 54 in the second quarter. Ascendis’s fund count moved from 47 in the first quarter to 49 in the second quarter. These figures describe ownership changes, but they do not establish that the settlement caused either shift.

Winners & Losers

• BioMarin Pharmaceutical Inc. (BMRN): Yahoo Finance reports that BioMarin receives royalties on Yuviwel net sales and agreed to drop the Section 337 investigation. The potential benefit is a sales-linked payment stream through May 20, 2030, while the amount ultimately realized depends on Yuviwel sales that are not provided.
• Ascendis Pharma A/S (ASND): Ascendis gains a non-exclusive, worldwide, royalty-bearing license for navepegritide and an agreed path to continue studying, developing, manufacturing and commercializing Yuviwel. The cost is a 20% US royalty and an 18% royalty in the European Union, Brazil and South Korea through May 20, 2030.
• Achondroplasia drug market: The settlement resolves a dispute between companies with competing achondroplasia treatments. Yahoo Finance reports that the agreement removes the pending litigation framework, but it does not provide market-share data or future demand estimates.

Risk Check

• Definitive documentation: Ascendis described the arrangement as a binding term sheet awaiting a definitive agreement. The definitive agreement referenced by Ascendis is not provided in the fact sheet.
• Sales dependence: BioMarin’s royalty value depends on Yuviwel net sales, and future Yuviwel sales are not provided. A royalty percentage alone does not establish the eventual cash amount.
• Margin burden: The 20% US and 18% international royalties apply through May 20, 2030. Yahoo Finance’s reported terms therefore create a continuing deduction from Ascendis’s Yuviwel net economics during that period.
• Regulatory and legal context: Ascendis’s medicine was under FDA assessment when BioMarin alleged infringement, and the dispute involved both the US International Trade Commission and federal litigation. The settlement resolves the litigation described by Yahoo Finance, but the fact sheet does not provide additional regulatory outcomes.

Bottom Line

Yahoo Finance’s reported 5% BioMarin share gain reflects a settlement that converts a global patent dispute into a defined royalty arrangement and removes the company’s Section 337 investigation. Ascendis obtains a worldwide license for navepegritide and continued commercialization flexibility, but pays 20% of US Yuviwel net sales and 18% in the European Union, Brazil and South Korea through May 20, 2030. The central investor checkpoint is Yuviwel’s actual sales trajectory relative to that royalty burden; the fact sheet supplies no sales forecast, upfront payment or total settlement value.

FAQ

What did BioMarin and Ascendis settle?

BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S announced a binding global patent settlement concerning Ascendis’s achondroplasia drug Yuviwel, Yahoo Finance reports. The settlement resolves litigation pending in numerous jurisdictions, including BioMarin’s Section 337 investigation at the US International Trade Commission.

How much will Ascendis pay BioMarin for Yuviwel?

Ascendis will pay BioMarin royalties equal to 20% of Yuviwel net sales in the United States and 18% of net sales in the European Union, Brazil and South Korea. Yahoo Finance reports that the payments run through May 20, 2030, with the US royalty retroactive to Yuviwel’s first commercial sale.

What license does Ascendis receive?

BioMarin will provide Ascendis a non-exclusive, worldwide, royalty-bearing license for navepegritide, Yuviwel’s active compound. According to Yahoo Finance, the license permits Ascendis to continue studying, developing, manufacturing and commercializing the medication without restrictions.

This article was independently written by OneDayTrading from public reporting. Read the original (Yahoo Finance)